Omnitech InfoSolutions Ltd, a provider of technology related services in the areas of business availability and business continuity, has signed a multi-year contract with two overseas companies to offer Remote Infrastructure management services and Virtual CIO offerings respectively.

According to official release, the consolidated and accumulative deal size would be at Rs 25 crore.

The company has signed the first contract with a European firm - IT Factory to remotely support IT Factory's management functions and IT maintenance.

Aurobindo Pharma, one of the largest API manufacturers in Asia, on Wednesday received its first approval from Swissmedic, Government of Switzerland for the license of Finasteride APL Tablets 5mg.

The drug is generic equivalent of MERCK & CO., Inc's Proscar Tablet.

Finasteride APL Tablet 5mg is used alone or in combination with another medication to treat benign prostatic hypertrophy (BPH, enlargement of the prostate gland). The drug is seen very effective in symptoms of BPH such as frequent and difficult urination. In addition, it also may decrease the chance of needing prostate surgery.

Hindustan Dorr Oliver Ltd, a leading total engineering solution provider company, has bagged two prestigious Orders in Mineral Sector worth Rs 66 crore from Vedanta Group.

The company secured first order worth Rs 48.5 crore from Vedanta Group for their 12.5 LTPA Aluminium Smelter Expansion Project at Jharsuguda.

Mumbai-based Gammon India Ltd has notified that it has secured a project c

For the year ending March 31, 2009, the turnover of the Power Sector Southern Region (PSSR) division - which is the engineering, procurement and construction wing of the state-managed Bharat Heavy Electricals Ltd (BHEL) - has crossed the Rs. 1,000-crore mark! The precise turnover figures stand at Rs. 1,000.40 crore as compared to the earlier year figures of Rs. 675 crore.

In a latest development, Hyderabad-based drug developer Suven Life Sciences has informed that its molecule for Alzheimer's disease will soon enter phase two trials.

According to sources, the phase two trials will cost the company $20 million. The company is presently in the process of raising funds for the trials through a combination of debt, equity and strategic partner.

Last week, the company announced that more than half-a-dozen companies have shown interest in partnering the company for developing 'SUVN 502' molecule.